Bone Fracture – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Bone Fracture – Pipeline Review, H2 2019’, provides an overview of the Bone Fracture pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Fracture, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Bone Fracture

– The report reviews pipeline therapeutics for Bone Fracture by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Bone Fracture therapeutics and enlists all their major and minor projects

– The report assesses Bone Fracture therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Bone Fracture”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bone Fracture

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Bone Therapeutics SA

ethris GmbH

Hemostemix Inc

Kuros Biosciences AG

Laboratorios SALVAT SA

Theragnostic Technologies Inc

USV Pvt Ltd

Viking Therapeutics Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bone Fracture Overview

Bone Fracture Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bone Fracture Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bone Fracture Companies Involved in Therapeutics Development

Biopharm GmbH

Bone Therapeutics SA

Entera Bio Ltd

ethris GmbH

Hemostemix Inc

Kolon TissueGene Inc

Kuros Biosciences AG

Laboratorios SALVAT SA

Novartis AG

Viking Therapeutics Inc

Bone Fracture Drug Profiles

ALLOB Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCP-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimagrumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyndacel-M Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Bone Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate BMP2 and VEGF for Bone Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HCSVT-1001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KUR-111 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KUR-113 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Activate BMP-2 for Bone Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Agonize PTH1R for Bone Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-008399 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Metabolic and Musculoskeletal Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Musculoskeletal and Metabolic Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Osteoporosis and Bone Fracture Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-B Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VK-5211 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bone Fracture Dormant Projects

Bone Fracture Discontinued Products

Bone Fracture Product Development Milestones

Featured News & Press Releases

Jul 17, 2018: Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting

Feb 19, 2018: Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB

Nov 28, 2017: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture

Sep 25, 2017: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings

Sep 20, 2017: Bone Therapeutics: announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis

Sep 14, 2017: Bone Therapeutics: Reports strong interim results from ALLOB Phase IIA spinal fusion study

Jul 12, 2017: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture

Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study

Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial

Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016

May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study

Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells’ Conference

Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial

Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture

Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Bone Fracture, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Bone Fracture – Pipeline by Bone Therapeutics SA, H2 2019

Bone Fracture – Pipeline by ethris GmbH, H2 2019

Bone Fracture – Pipeline by Hemostemix Inc, H2 2019

Bone Fracture – Pipeline by Kuros Biosciences AG, H2 2019

Bone Fracture – Pipeline by Laboratorios SALVAT SA, H2 2019

Bone Fracture – Pipeline by Theragnostic Technologies Inc, H2 2019

Bone Fracture – Pipeline by USV Pvt Ltd, H2 2019

Bone Fracture – Pipeline by Viking Therapeutics Inc, H2 2019

Bone Fracture – Dormant Projects, H2 2019

Bone Fracture – Dormant Projects, H2 2019 (Contd..1), H2 2019

Bone Fracture – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Bone Fracture, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports